{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:12:25Z","timestamp":1779358345742,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:00:00Z","timestamp":1255737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00125-009-1568-4","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T13:50:09Z","timestamp":1255701009000},"page":"2507-2512","source":"Crossref","is-referenced-by-count":89,"title":["No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis"],"prefix":"10.1007","volume":"52","author":[{"given":"A.","family":"Dejgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lynggaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"R\u00e5stam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Krogsgaard Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,17]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","volume":"52","author":"LG Hemkens","year":"2009","unstructured":"Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732\u20131744","journal-title":"Diabetologia"},{"key":"1568_CR2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","volume":"52","author":"JM Jonasson","year":"2009","unstructured":"Jonasson JM, Ljung M, Talb\u00e4ck M et al (2009) Insulin glargine use and short-term incidence of malignancies\u2014a population-based follow-up study in Sweden. Diabetologia 52:1745\u20131754","journal-title":"Diabetologia"},{"key":"1568_CR3","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","volume":"52","author":"CJ Currie","year":"2009","unstructured":"Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766\u20131777","journal-title":"Diabetologia"},{"key":"1568_CR4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","volume":"52","author":"HM Colhoun","year":"2009","unstructured":"Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology. Diabetologia 52:1755\u20131765 Erratum doi: 10.1007\/s00125-009-1453-1","journal-title":"Diabetologia"},{"key":"1568_CR5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00125-009-1441-5","volume":"52","author":"U Smith","year":"2009","unstructured":"Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699\u20131708","journal-title":"Diabetologia"},{"key":"1568_CR6","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/aje\/kwh161","volume":"159","author":"SS Coughlin","year":"2004","unstructured":"Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160\u20131167","journal-title":"Am J Epidemiol"},{"key":"1568_CR7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/jnci\/89.18.1360","volume":"89","author":"L Wideroff","year":"1997","unstructured":"Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360\u20131365","journal-title":"J Natl Cancer Inst"},{"key":"1568_CR8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1534735403259152","volume":"2","author":"DB Boyd","year":"2003","unstructured":"Boyd DB (2003) Insulin and cancer. Integr Cancer Ther 2:315\u2013329","journal-title":"Integr Cancer Ther"},{"key":"1568_CR9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","volume":"49","author":"P Kurtzhals","year":"2000","unstructured":"Kurtzhals P, Schaeffer l, S\u00f8rensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999\u20131005","journal-title":"Diabetes"},{"key":"1568_CR10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505\u2013518","journal-title":"Nat Rev Cancer"},{"key":"1568_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1677\/ERC-08-0240","volume":"16","author":"A Shukla","year":"2009","unstructured":"Shukla A, Grisourd J, Ehemann V et al (2009) Analysis of signalling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429\u2013441","journal-title":"Endocr Relat Cancer"},{"key":"1568_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1054\/ghir.2001.0256","volume":"11","author":"D Yee","year":"2001","unstructured":"Yee D (2001) Are the insulin-like growth factors relevant to cancer. Growth Horm IGF Res 11:339\u2013345","journal-title":"Growth Horm IGF Res"},{"key":"1568_CR13","unstructured":"FDA Levemir pharmacology review (2005) Available from www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021-536_LevemirTOC.cfm , accessed 30 September 2009"},{"key":"1568_CR14","doi-asserted-by":"crossref","DOI":"10.1002\/0470854200","volume-title":"Meta-analysis of controlled clinical trials","author":"A Whitehead","year":"2002","unstructured":"Whitehead A (2002) Meta-analysis of controlled clinical trials. Wiley, Chichester"},{"key":"1568_CR15","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896\u20131900","journal-title":"Lancet"},{"key":"1568_CR16","unstructured":"The European Agency for the Evaluation of the Medicinal Products: Evaluation of medicines for human use. Committee for Proprietary Medicinal Produces (CPMP). Points to consider on validity and interpretation of meta-analyses, and one pivotal study (2000) Available from www.emea.europa.eu\/pdfs\/human\/ewp\/233099den.pdf , accessed 30 September 2009"},{"key":"1568_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"1568_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/sim.4780060306","volume":"6","author":"R Peto","year":"1987","unstructured":"Peto R (1987) Why do we need systematic overviews of randomised trials? Stat Med 6:233\u2013240","journal-title":"Stat Med"},{"key":"1568_CR19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, Colins R, Sleight P (1985) Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335\u2013371","journal-title":"Prog Cardiovasc Dis"},{"key":"1568_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Localio AR (2007) Much ado about nothing: a comparison of the performance of meta-analytic methods with rare events. Stat Med 26:53\u201377","journal-title":"Stat Med"},{"key":"1568_CR21","unstructured":"The Cochrane policy manual: The Cochrane Collaboration. The Cochrane policy manual 2009, issue 3 (updated 11 May 2009) (2009) Available from http:\/\/Cochrane.org\/admin\/The_Cochrane_Policy_Manual_20110509.pdf , accessed 30 September 2009"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-009-1568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-009-1568-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-009-1568-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:47:15Z","timestamp":1558612035000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-009-1568-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,17]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s00125-009-1568-4","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,17]]}}}